

Stephen Opat

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2542264/stephen-opat-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113
papers

4,045
citations

24
h-index

63
g-index

119
ext. papers

5,273
ext. citations

5.8
avg, IF

4.78
L-index

#	Paper	IF	Citations
113	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.. <i>Blood</i> , 2022 ,	2.2	10
112	Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia. <i>Cancers</i> , 2022 , 14, 2710	6.6	1
111	Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience. <i>Internal Medicine Journal</i> , 2021 , 51, 1825-1834	1.6	
110	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort. <i>Blood Advances</i> , 2021 ,	7.8	6
109	Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA). <i>Blood</i> , 2021 , 138, 2532-2532	2.2	
108	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021 , 138, 396-396	2.2	6
107	A Window Study of Acalabrutinib Plus Rituximab Followed By R-Dhaox (rituximab, dexamethasone, cytarabine, oxaliplatin) and Autologous Stem Cell Transplant (ASCT) in Fit Mantle Cell Lymphoma (MCL): The Australasian Leukaemia & Lymphoma Group (ALLG) NHL33 Wamm Trial. <i>Blood</i> , 2021 ,	2.2	
106	Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib. <i>Blood</i> , 2021 , 138, 1419-1419	2.2	0
105	Real World Data on the Outcomes of Richter's Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study. <i>Blood</i> , 2021 , 138, 1455-1455	2.2	
104	First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study. <i>Blood</i> , 2021 , 138, 68-68	2.2	3
103	Salvage radiotherapy is associated with durable response for a subset of patients with limited-stage refractory DLBCL. <i>Blood Advances</i> , 2021 , 5, 5112-5115	7.8	0
102	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3853-3865	2.2	17
101	WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes. <i>American Journal of Hematology</i> , 2021 , 96, E218-E222	7.1	4
100	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2021 , 5, 2577-2585	7.8	17
99	A Description of the Type, Frequency and Severity of Infections Among Sixteen Patients Treated for T-Cell Lymphoma. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021 , 10, 123-129	0.8	
98	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. <i>Leukemia and Lymphoma</i> , 2021 , 62, 112-117	1.9	2
97	Impact of coronavirus disease 2019 (COVID-19) pandemic isolation measures on the rate of non-COVID-19 infections in hematology patients. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 42, 233-235	2	0

96	An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2021 , 17, 371-387	3.6	0
95	Safety of rapid injection of undiluted ferric carboxymaltose to patients with iron-deficiency anaemia: a Phase II single-arm study. <i>Internal Medicine Journal</i> , 2021 , 51, 1304-1311	1.6	0
94	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 6323-6332	12.9	9
93	Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 1329-1344	3.8	4
92	Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.. <i>British Journal of Haematology</i> , 2021 ,	4.5	5
91	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020 , 4, 6009-6018	7.8	20
90	ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8007-8007	2.2	8
89	A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.	1.6	6
88	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2020 , 21, 1433-1442	21.7	114
87	Caution in Expanding the Use of Abbreviated R-CHOP to Poor-Risk Limited-Stage DLBCL. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4221-4222	2.2	0
86	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. <i>Blood</i> , 2020 , 136, 2027-2037	2.2	33
85	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020 , 136, 2038-2050	2.2	110
84	Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 997-1003	5.1	4
83	Failure of tofacitinib to achieve an objective response in a T-lymphoblastic leukemia with activating mutations. <i>Journal of Physical Education and Sports Management</i> , 2020 , 6,	2.8	2
82	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 1188-1200	21.7	92
81	Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. <i>Scientific Reports</i> , 2019 , 9, 13544	4.9	6
80	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2019 , 380, 2225-2236	59.2	368
79	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. <i>Hematological Oncology</i> , 2019 , 37, 253-260	1.3	2

78	Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. <i>Internal Medicine Journal</i> , 2019 , 49, 1070-1080	1.6	5
77	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. <i>Blood</i> , 2019 , 134, 851-859	2.2	151
76	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2019 , 134, 35-35	2.2	30
75	Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma. <i>Blood</i> , 2019 , 134, 5256-5256	2.2	2
74	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. <i>Blood</i> , 2019 , 134, 499-499	2.2	19
73	Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial. <i>Blood</i> , 2019 , 134, 500-500	2.2	16
72	An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies. <i>Blood</i> , 2019 , 134, 1594-1594	2.2	5
71	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2019 , 134, 123-123	2.2	24
70	The Real World Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. <i>Blood</i> , 2019 , 134, 3986-3986	2.2	0
69	Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. <i>Blood</i> , 2019 , 134, 1600-1600	2.2	2
68	Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS. <i>HemaSphere</i> , 2019 , 3, e187	0.3	8
67	Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma. <i>Internal Medicine Journal</i> , 2019 , 49, 422-433	1.6	5
66	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 229-240	4.0	283
65	Bleeding and thrombotic events occur early in children on durable ventricular assist devices. <i>Thrombosis Research</i> , 2019 , 173, 65-70	8.2	6
64	Anti-CD20 monoclonal antibodies: reviewing a revolution. <i>Human Vaccines and Immunotherapeutics</i> , 2018 , 14, 2820-2841	4.4	35
63	Concurrent Mycobacterium tuberculosis infection and nodal marginal zone lymphoma. <i>Pathology</i> , 2018 , 50, 464-466	1.6	
62	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018 , 132, 4196-4196	2.2	9
61	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018 , 132, 4097-4097	2.2	3

60	Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018 , 132, 1592-1592	2.2	6
59	Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome. <i>Blood</i> , 2018 , 131, 699-702.2		4
58	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1530-1542	21.7	59
57	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Blood</i> , 2017 , 129, 2702-2705	2.2	90
56	Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1331-1344	59.2	365
55	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, S380-S381	2	2
54	High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2017 , 178, 991-994	4.5	6
53	Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. <i>Blood Advances</i> , 2016 , 1, 31-35	7.8	38
52	Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. <i>Annals of Hematology</i> , 2016 , 95, 667-8	3	18
51	High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study. <i>Blood</i> , 2016 , 128, 1216-1216	2.2	9
50	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1874-1874	2.2	2
49	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). <i>Blood</i> , 2016 , 128, 2054-2054	2.2	8
48	Improved Survival of Older Patients with Mantle Cell Lymphoma (MCL) with Front-Line Cytarabine-Based Immunochemotherapy. <i>Blood</i> , 2016 , 128, 2965-2965	2.2	2
47	Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. <i>Blood</i> , 2016 , 128, 6-6	2.2	23
46	Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016 , 128, 642-642	2.2	22
45	Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services. <i>Internal Medicine Journal</i> , 2016 , 46, 964-9	1.6	5
44	The oral iron chelator deferasirox inhibits NF- κ B mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia. <i>British Journal of Haematology</i> , 2015 , 168, 576-82	4.5	26
43	Disseminated Enteroviral Infection Associated with Obinutuzumab. <i>Emerging Infectious Diseases</i> , 2015 , 21, 1661-3	10.2	17

42	Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression. <i>Blood</i> , 2015 , 126, 3457-3457	2.2	2
41	Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. <i>Blood</i> , 2015 , 126, 496-496	2.2	14
40	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. <i>Blood</i> , 2015 , 126, 832-832	2.2	79
39	Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. <i>New England Journal of Medicine</i> , 2014 , 370, 1101-10	59.2	1048
38	A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2014 , 111, 1072-9	8.7	79
37	Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. <i>Neuro-Oncology</i> , 2013 , 15, 1068-73	1	45
36	Factor XIII assays. <i>Methods in Molecular Biology</i> , 2013 , 992, 171-80	1.4	2
35	ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. <i>New England Journal of Medicine</i> , 2013 , 368, 90-2	59.2	90
34	High-dose cytarabine (24 g/m ²) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. <i>Internal Medicine Journal</i> , 2013 , 43, 294-7	1.6	9
33	Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2013 , 122, 4353-4353	2.2	4
32	Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. <i>Blood</i> , 2013 , 122, 6-6	2.2	12
31	SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. <i>Blood</i> , 2013 , 122, 86-86	2.2	8
30	Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7004-7004	2.2	18
29	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. <i>Blood</i> , 2012 , 119, 1963-71	2.2	264
28	A case of ITP with cauda equina syndrome. <i>Annals of Hematology</i> , 2011 , 90, 729-30	3	
27	Failure of eculizumab to correct paroxysmal cold hemoglobinuria. <i>Annals of Hematology</i> , 2011 , 90, 989-99		24
26	Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia. <i>Journal of Medical Microbiology</i> , 2011 , 60, 142-146	3.2	11
25	Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML. <i>Blood</i> , 2011 , 118, 2599-2599	2.2	1

24	Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study. <i>Blood</i> , 2011 , 118, 5050-5050	2.2	20
23	Allo-SCT for hematological malignancies in the setting of HIV. <i>Bone Marrow Transplantation</i> , 2010 , 45, 584-6	4.4	12
22	Molecular Analysis of the SEC23B Gene In Patients Affected by Congenital Dyserythropoietic Anemia Type II (CDAll). <i>Blood</i> , 2010 , 116, 4227-4227	2.2	1
21	Whole Brain Radiotherapy and Ara-C In Consolidation Post High-Dose Methotrexate Is Important In Establishing Durable Disease Control In the Treatment of Primary CNS Lymphoma: A Single Centre Observational Study. <i>Blood</i> , 2010 , 116, 1776-1776	2.2	
20	Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1964-8	1.9	2
19	Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. <i>Clinical Cancer Research</i> , 2009 , 15, 714-22	12.9	24
18	Burkitt lymphoma in the setting of common variable immunodeficiency. <i>Annals of Hematology</i> , 2009 , 88, 819-20	3	3
17	Bone marrow engraftment in pulmonary vessels. <i>British Journal of Haematology</i> , 2009 , 146, 2	4.5	
16	Aplastic anaemia: autoimmune sequel of thymoma. <i>British Journal of Haematology</i> , 2009 , 147, 591	4.5	8
15	The thrombotic thrombocytopenic purpura registry: a new national resource to inform patient care and medical research. <i>Internal Medicine Journal</i> , 2009 , 39, 72-3	1.6	
14	The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.. <i>Blood</i> , 2009 , 114, 2923-2923	2.2	1
13	Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2009 , 114, 3944-3944	2.2	1
12	A drop of vitriol: microspherocytosis following sulphuric acid exposure. <i>British Journal of Haematology</i> , 2008 , 140, 596	4.5	3
11	Oxidative haemolysis due to SoppersS <i>British Journal of Haematology</i> , 2008 , 142, 328	4.5	
10	Antiplatelet therapy: present status and future prospects. <i>Expert Opinion on Drug Discovery</i> , 2007 , 2, 1035-40	6.2	1
9	Allogeneic Peripheral Blood Stem Cell Transplantation for Hematological Malignancies in Patients with HIV.. <i>Blood</i> , 2007 , 110, 4941-4941	2.2	2
8	The Feasibility and Safety of Anticoagulation during Chemotherapy Associated Thrombocytopenia for Thrombotic Complications of Malignancy.. <i>Blood</i> , 2007 , 110, 1872-1872	2.2	
7	The Utility of Radionuclide Ventriculography (RNV) Prior to Anthracycline Chemotherapy in Patients with Acute Myeloid Leukemia: A Retrospective, Single Institution Study.. <i>Blood</i> , 2007 , 110, 4369-4369	2.2	2

6	An unusual case of indigestion: persistence of phagocytosed Auer rods in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2006 , 133, 112	4.5	2
5	The Clinical Utility of the 1-Deamino-8-D-Arginine Vasopressin (DDAVP) Trial in the Management of Patients with Von Willebrand Disease: A Retrospective Study.. <i>Blood</i> , 2006 , 108, 1033-1033	2.2	
4	A Novel Fusion of RARA to the PRKAR1A Gene, Encoding the Regulatory Subunit Type-I of Cyclic AMP Dependent Protein Kinase A, in a Variant Acute Promyelocytic Leukaemia.. <i>Blood</i> , 2006 , 108, 2343-2343	2.2	
3	Failure of rituximab monotherapy in lymphomatoid granulomatosis. <i>European Journal of Haematology</i> , 2005 , 75, 172-3	3.8	17
2	The recognition of HLA-B27 by human CD4(+) T lymphocytes. <i>Journal of Immunology</i> , 2001 , 167, 2619-245.3	5.3	96
1	Disseminated echovirus infection after allogeneic bone marrow transplantation. <i>Pathology</i> , 1997 , 29, 424-5	1.6	4